Protalix BioTherapeutics (PLX) Research & Development (2010 - 2026)

Protalix BioTherapeutics has reported Research & Development for 17 years, with the latest figure at $4.4 million in Q2 2026.

• On a quarterly basis, Research & Development fell 27.39% year-over-year to $4.4 million in Q2 2026; TTM through Jun 2026 was $19.9 million, a 19.83% increase from a year earlier, with the FY2025 full-year figure at $19.6 million, up 50.88% from the prior year.
• Research & Development was $4.4 million for Q2 2026 at Protalix BioTherapeutics, down from $5.4 million in the prior quarter.
• The five-year high for Research & Development was $8.8 million in Q1 2022, with the low at $2.9 million in Q1 2024.
• Average Research & Development over 5 years is $4.9 million, with a median of $4.5 million recorded in 2023.
• The sharpest annual moves came in 2024 and 2025: Research & Development tumbled 50.62% in 2024, then soared 102.36% in 2025.
• Over 5 years, Research & Development stood at $5.6 million in 2022, then slumped by 44.77% to $3.1 million in 2023, then soared by 32.95% to $4.1 million in 2024, then surged by 36.64% to $5.6 million in 2025, then retreated by 22.79% to $4.4 million in 2026.
• The last three Research & Development figures came in at $4.4 million (Q2 2026), $5.4 million (Q1 2026), and $5.6 million (Q4 2025), per Business Quant data.